Castle Biosciences, Inc.
CSTL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $0 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 51.1% | 60.4% | 45.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 81.9% | 79.5% | 76.6% | 83.2% |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 11.5% | -20.5% | -42.6% | -38.9% |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 5.5% | -26.1% | -49% | -33.3% |
| EPS Diluted | 0.62 | -2.14 | -2.58 | -1.24 |
| % Growth | 129% | 17.1% | -108.1% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |